Pancreatic cancer pill that doubled survival may get Canada clinical trial

A clinical trial for the experimental drug daraxonrasib, which has shown the potential to double survival rates for pancreatic cancer patients, may soon take place in Canada. Medical oncologist Dr. Jennifer Knox has independently reviewed a U.S.-led study on the drug and described the results as 'amazing.'

This development is significant as it could provide new hope for pancreatic cancer patients, a group that historically faces poor survival rates. The successful trial could lead to broader access to this promising treatment in Canada and potentially improve patient outcomes.